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Abstract
The ABCG2 multidrug transporter provides resistance against various endo- and xenobiot-
ics, and protects the stem cells against toxins and stress conditions. We have shown earlier
that a GFP-tagged version of ABCG2 is fully functional and may be used to follow the
expression, localization and function of this transporter in living cells. In the present work we
have overexpressed GFP-ABCG2, driven by a constitutive (CAG) promoter, in HUES9
human embryonic stem cells. Stem cell clones were generated to express the wild-type and
a substrate-mutant (R482G) GFP-ABCG2 variant, by using the Sleeping Beauty transposon
system. We found that the stable overexpression of these transgenes did not change the
pluripotency and growth properties of the stem cells, nor their differentiation capacity to
hepatocytes or cardiomyocytes. ABCG2 overexpression provided increased toxin resis-
tance in the stem cells, and protected the derived cardiomyocytes against doxorubicin toxic-
ity. These studies document the potential of a stable ABCG2 expression for engineering
toxin-resistant human pluripotent stem cells and selected stem cell derived tissues.
Introduction
ATP-binding cassette multidrug transporter proteins (MDR-ABC) actively extrude many
types of xenobiotics and drugs from the cells, protect our tissues against harmful metabolites
and contribute to the resistance of cancer cells against chemotherapy [1]. The most significant
human MDR-ABC transporters are ABCG2, ABCB1 and ABCC1, which form a special che-
moimmunity network [2]. The ABCG2 protein is a half-transporter, physiologically highly
expressed in the liver, intestine, kidney and the tissue barriers, contributing to remove both
endo- and xenobiotics, including the toxic compounds of porphyrin metabolism [3–7]. The
ABCG2 protein has also been identified in many types of tissue-derived stem cells and in
human embryonic stem cell lines (hESC) [8,9]. We have first shown the presence of the
ABCG2 transporter in the HUES cell lines and demonstrated the protecting role of this trans-
porter under different stress conditions [10,11]. We have also documented the heterogeneous
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expression of ABCG2 in hESCs, and found a dynamic balance of ABCG2 expression at the
stem cell population level [11].
In the present study, in order to apply a suitably tagged ABCG2 which can be easily fol-
lowed and visualized in living cells, we used a GFP-ABCG2 fusion protein, shown to be fully
functional and correctly processed in various cell types [12]. Moreover, a stable expression of
this GFP-ABCG2 in hESCs, by using the Sleeping Beauty transposon system and a CAG pro-
moter, has already been successfully performed by our group [13].
There are several mutant variants of the ABCG2 transporter, which significantly affect the
function of this protein. First found in drug-selected cancer cell lines, the R482G-ABCG2 vari-
ant was shown to have different substrate recognition and regulation properties [14,15], pro-
viding increased resistance against toxic agents, e.g. doxorubicin, than the wild-type protein.
In the present study we have generated the GFP fusion constructs of the wild-type and the
R482G ABCG2 variants, and characterized their expression, function and trafficking in stem
cells. While we did not see an effect of ABCG2 expression on the pluripotency markers, the
growth properties, and the morphology of hESCs, they showed an increased resistance against
mitoxantrone.
In addition to the characterization of GFP-ABCG2 overexpressing hESCs, we performed
detailed differentiation studies, and found a preserved expression and membrane localization
of the GFP-ABCG2 variants in the stem cell derived cardiomyocytes and hepatocytes. Since
the CAG promoter is especially efficient in cardiac tissues, we examined the potential protec-
tive effect of ABCG2 in cardiomyocytes. Indeed, we found that the stem cell derived ABC-
G2-expressing cardiomyocytes, with preserved beating function, were significantly protected
against doxorubicin toxicity.
Materials and methods
Maintenance of the undifferentiated human embryonic stem cell lines
Research involving human embryonic stem cells has been approved Hungarian Medical
Research Council (6681/2012/HER) and this study was reviewed and approved by a specific
ethics committee (Human Reproduction Committee, HRB) of the Hungarian Medical
Research Council. The HUES9 human embryonic stem cell line (originally provided by Doug-
las Melton, Harvard University, in 2005 [16]), its EGFP-expressing derivative (HUES9-EGFP)
and GFP-ABCG2 variants expressing HUES9 cell lines were maintained essentially as
described before [8]. The cells were cultured on mitomycin-C-treated mouse embryonic fibro-
blast (MEF) feeder cells in tissue culture 6-well plates (Nunc). The culture medium consisted
of 15% Knockout Serum Replacement (Gibco) in Knockout Dulbecco Modified Eagle Medium
(Gibco), supplemented with 1 mM Glutamax-I (Gibco), 0.1 mM beta-mercaptoethanol, 1%
nonessential amino acids, and 4 ng/mL human fibroblast growth factor (Invitrogen). The
media were changed daily and the cells were re-plated every second day onto fresh feeder lay-
ers by enzymatic dissociation with 0.025% trypsin-EDTA (Invitrogen). In certain experiments
we applied the previously generated and characterized EGFP transgene expressing HUES9
cells, as a control. These EGFP-expressing cells are similar to the parental HUES9 cells in
terms of their pluripotency and differentiation properties [13].
Generation of HUES9 clones expressing GFP-ABCG2 variants
The cDNAs coding for three variants of ABCG2 (wild-type (R482R), R482G, and K86M, see
S1 Fig) were transfected together with the SB transposase into hESCs. After 2 days of transfec-
tion, we sorted the cells stably expressing GFP-ABCG2, based on the GFP fluorescence by
using flow cytometry. After sorting, the cell cultures were maintained in 0.8 μg/ml puromycin
ABCG2 expression in hES cells
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containing media and the GFP-ABCG2 expressing clones were picked mechanically. After the
establishment of stable GFP-ABCG2 expressing hESC clones, we measured the integrated
copy number of the transgenes, based on the IRDR L sequences [17]. We found that the inte-
grated copy numbers in the HUES9 cells were 8 for the wt GFP-ABCG2 R482R, 6 for
GFP-ABCG2 R482G and 4 for the GFP-ABCG2 K86M variants.
Spontaneous differentiation and cardiomyocyte separation
Spontaneous differentiation of the HUES9 and GFP-ABCG2 variants expressing HUES9 cells
were performed via embryoid body (EB) formation, as described previously [18]. After 6 days,
the EB were placed onto gelatin coated 24 well plates, where they attached to the surface and
underwent spontaneous differentiation. Immunostainings of spontaneously differentiating
samples were performed at day 6, while real-time PCR measurements were performed at days
6, 12 and 18. For characterization of hESC-derived cardiomyocytes the rhythmically contract-
ing areas were isolated mechanically, and re-plated on gelatin coated 8-well confocal chambers
[19]. The immunostaining and doxorubicin treatments were performed at day 24.
Hepatic differentiation
The differentiation protocol was based on Si-Tayeb et al. 2010 [20] and Cai et al. 2012 [21] pro-
tocols, adapted to HUES9 cells. Briefly, to initiate differentiation, HUES9 cells at ~70% conflu-
ence in 6-well plates were treated with Accutase (Stem Cell Technologies) and transferred to
Matrigel-coated (50 μg/ml) 12 well plates (3x105/cm2), and cultured for 24–36 hours to reach
~90% confluence (0–2 days). During this time, mTeSR1 (Stem Cell Technologies) media were
applied at 37˚C and 5% CO2. At the beginning of the differentiation, for endoderm formation,
the media were replaced with RPMI supplemented with 2% B27-minus insulin (Gibco), 100
ng/ml Activin A, 10 ng/ml BMP4 and 20 ng/ml FGF2 (all from Peprotech) for two days, with
daily media changes at 37˚C and 5% CO2. In the next 3 days the BMP4 and FGF2 were leaved
out from the media, otherwise the same conditions were applied (3–7 days). Hepatic specifica-
tion was stimulated by RPMI media containing B27-plus insulin (Gibco), 20 ng/ml BMP4 and
10 ng/ml FGF2 (all from Peprotech) for five days at 37˚C and 5% CO2, and the media were
replaced daily (8–12). The next 5 days RPMI supplemented with B27-plus insulin, human
recombinant HGF 20 ng/ml (Peprotech) was applied with daily media changes at 37˚C and 5%
CO2 (13–17 days). At the end of the differentiation the medium was changed to Hepatocyte
Culture Medium Clonetics HCM (Lonza CC-3198) containing ‘Singlequots’, however the EGF
was omitted, and Oncostatin M 20 ng/ml (Peprotech) supplement was added (18–22 days).
The media were changed daily for 5 days at 37˚C and 5% CO2.
Immunocytochemical staining—confocal microscopy
For immunofluorescence staining, undifferentiated and differentiated HUES9 parental and
GFP-ABCG2 expressing HUES9 cells were seeded onto Matrigel coated (50 μg/mL) Imaging
dishes (Zellkontakt). For labeling of pluripotency markers and the differentiation markers, we
used the following primary antibodies: Oct4 (mouse, monoclonal, 1:50, SantaCruz,), cardiac
Troponin-I (mouse monoclonal, 1:300, Sigma), beta-III Tubulin (mouse, monoclonal, 1:2000,
RnD Systems), anti-human alpha Fetoprotein (AFP) (mouse, monoclonal, 1:500, Sigma), anti-
alpha smooth muscle actin (SMA) (mouse, monoclonal, 1:100, Abcam), HNF4 (rabbit, poly-
clonal, 1:100, Abcam) and CK18 (mouse, monoclonal, 1:100, Abcam). As a primary antibody
against GFP, anti-GFP (rabbit, polyclonal, 1:500, Abcam or chicken, polyclonal, 1:250, AVES)
was used. 1 μM DAPI (Thermo Fisher Scientific) was used for nuclear staining. The stained
ABCG2 expression in hES cells
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samples were examined by a Zeiss LSM710 confocal laser scanning microscope, using Plan-
Apochromat 20x (0.8) air objective (Zeiss) at 405, 488 and 633 nm excitations, respectively.
Flow cytometry analysis
Cells were suspended in PBS, containing 0.5% bovine serum albumin, and labeled with a com-
bination of monoclonal antibodies (mAbs). For all samples an anti-mouse Sca-1 (Ly-6A/E) PE
or FITC (BD Pharmingen) antibody was used, for gating out the positively labeled mouse
feeder cells. For specific labeling of HUES9 cells we used the directly labeled anti-human
SSEA4-APC antibody (R&D System). Indirect staining of ABCG2 was performed by using the
5D3 monoclonal antibody, applied in the presence of 1 μM Ko143, a specific inhibitor of
ABCG2, which maximizes 5D3 binding [15]. The secondary antibody used was R-phycoery-
thrin conjugated goat anti-mouse IgG2b, (Invitrogen). Control staining with appropriate iso-
type-matched control mAbs was included.
Cells were incubated for 30 min at 37˚C with the antibodies, and dead cells were gated out
on the basis of 7AAD (Sigma) staining. Samples were analyzed by a FACSCanto flow cytome-
ter (Beckton-Dickinson) equipped with a 488 nm argon laser and a 635 nm red diode laser,
with CellQuest acquisition software (BDIS).
Real-time PCR analysis
Total RNA was isolated from cells by the use of TRIzol reagent (Invitrogen), in accordance
with the manufacturer’s instructions. cDNA samples were prepared from 0.5 μg total RNA by
using the Promega reverse transcription system kit, as specified by the manufacturer. For real-
time quantitative PCR, pre-developed Taq-Man assays were purchased from Applied Biosys-
tems, for detecting total ABCG2 (Hs01053790_m1), NANOG (HS02387400_g1), Oct4
(POU5F1- Hs00999632_g1), AFP (Hs00173490_m1), T-Brachyury (Hs00610080_m1), Pax6
(Hs00240871_m1) and PRLP0 ribosomal protein (Hs99999902_m1) mRNA, the latter used as
the internal control for quantification. We measured the mRNA levels of the Oct4 (POU5F1),
AFP (Hs00173490_m1), ALB (Hs00910225_m1), ABCB11 (Hs00184824_m1), and HNF4
(Hs00604435_m1) during hepatocyte differentiation. Relative mRNA levels were calculated by
using the 2-DDCt method. TaqMan assays were run and analyzed by using the StepOneTM
real-time PCR system (Applied Biosystems), in accordance with the manufacturer’s
instructions.
Dye cycle violet (DCV) transport measurements
We measured the transport function of the GFP-ABCG2 protein variants in HUES9 cells by
measuring Dye cycle violet (DCV) fluorescent dye uptake. In these experiments the cells were
incubated with 100 nM DCV for 16 hours, in the presence or absence of the ABCG2 specific
inhibitor Ko143. The DCV fluorescence signal, representing DNA-bound DCV, was followed
in the cells by flow cytometry. The transport activity of ABCG2 was characterized by the
“transport activity factor” (F), calculated as follows: (F100-F0)/F100 x100, where F0 is the fluo-
rescence (median values) of DCV-treated cells in the absence of an inhibitor; F100 is the fluo-
rescence (median values) in the presence of the inhibitor Ko143 [22].
Mitoxantrone (MX) toxicity
HUES9 or HUES9 cells expressing the GFP-ABCG2 variants were seeded onto mitomycin-
treated MEF cells. 24 hours later the cells were exposed to 5–200 nM Mitoxantrone (MX). The
culture media were changed on the second day. On the third day cells were collected from the
ABCG2 expression in hES cells
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MEF cells by trypsin treatment, and analyzed by flow cytometry. The survival of parental and
GFP-ABCG2 expressing HUES9 cells was measured based on propidium-iodide accumula-
tion. For all samples an anti-mouse Sca-1 (Ly-6A/E)-PE (Beckton-Dickinson) antibody was
used for gating out the positively labeled mouse feeder cells. The ratio of the dead and living
cells was calculated on the basis of propidium-iodide accumulation.
Doxorubicin treatment
The beating cardiomyocyte colonies derived from HUES9 parental and GFP-ABCG2–R482G
expressing HUES9 cells were isolated mechanically and re-plated onto gelatin coated 8 well
confocal chambers. After 2 days post-plating, the cells were incubated with 3 μM doxorubicin
(DOX) for 16 hours. DOX accumulation in the cells was examined by a Zeiss LSM710 confocal
laser scanning microscope, using a Plan-Apochromat 20x (0.8) air objective (Zeiss) at 458 nm
excitation and 535–595 nm emission wavelength. The survival of parental and GFP-ABCG2
expressing HUES9 derived cardiomyocytes was measured based on propidium-iodide accu-
mulation at 543 nm excitations and 662–797 nm emission wavelength and Hoechst33342 dye
accumulation at 405 nm excitations and 410–538 nm emission wavelength.
Results
Generation and characterization of hES cell clones expressing GFP-ABCG2
variants
In order to explore the effects of ABCG2 overexpression in hES cells, we have generated
HUES9 cells expressing a GFP-tagged version of ABCG2 protein and its variants, driven by a
constitutively active CAG promoter. For gene delivery and stable expression of the wild type
and the R482G-ABCG2 proteins we used the Sleeping Beauty transposon system (see Methods
and S1 Fig), as we have shown earlier that a GFP-tagged version of ABCG2 is fully functional
and can be efficiently used to follow the expression, trafficking and function of this transporter
in living cells [12]. As a control, we have also generated stem cells expressing a non-functional
K86M-ABCG2. hES clones containing 4–8 copies of the transgene and stably expressing the
GFP-ABCG2 variants were selected by puromycin, sorted by flow cytometry, and finally
picked mechanically (see Methods).
Confocal microscopy measurements (Fig 1A) of these clones showed that the GFP-ABCG2
protein was relatively uniformly expressed in the HUES9 cells, and why intracellular localiza-
tion was also observable, all three ABCG2 variants localized partially in the plasma membrane
of the living hES cells (Fig 1A). Flow cytometry measurements, by using the cell surface reac-
tive anti-ABCG2 antibody, 5D3, also confirmed a relatively high plasma membrane localiza-
tion of the GFP-ABCG2 in the transgenic clones (Fig 1B). From the numerous clones stably
expressing the GFP-ABCG2 protein, we have selected three relevant cell lines for further dif-
ferentiation studies.
In these experiments we have also examined how the overexpression of GFP-ABCG2
changes the pluripotency and the related marker expression of the hES cells. As documented
in Fig 1A, the expression of Oct-4 transcription factor protein was present in the nuclei of all
GFP-ABCG2 expressing hES clones. A similar, high level expression at the mRNA level was
observed for another key pluripotency marker, Nanog, in the GFP-ABCG2 expressing clones
as compared to the parental cell line (see S2 Fig). For further verifying the pluripotent state of
the GFP-ABCG2-hES cells, we also measured the expression of the cell surface marker SSEA-4
in the hESCs by using confocal microscopy (data not shown) and flow-cytometry (Fig 1C). As
shown in Fig 1C, the cell surface expression of SSEA4, measured by flow cytometry, was
ABCG2 expression in hES cells
PLOS ONE | https://doi.org/10.1371/journal.pone.0194925 April 12, 2018 5 / 17
uniformly high (over 92%) in the parental and in all HUES cell clones expressing the
GFP-ABCG2 variants. In these experiments we have also compared the growth properties of
the GFP-ABCG2-hESCs and parental hESCs cell lines. According the similar passaging times
and a cell proliferation assay with PrestoBlue, we found no difference between the growth
properties of the GFP-ABCG2 expressing and the parental HUES9 cells (data not shown). We
also examined the expression of the other main ABC transporters, ABCB1 and ABCC1 by RT-
qPCR and found that the overexpression of the ABCG2 variants did not alter the mRNA
Fig 1. Expression of the GFP-tagged ABCG2 variants in HUES9 cells. (A) Confocal images for HUES9 cell clumps expressing the
GFP-ABCG2 variants (green), HUES9 cells are cultured on mouse embryonic fibroblasts. Immunostaining for Oct4 (red), cell nuclei
are stained with DAPI (blue). (B) Flow cytometry analysis of HUES9 cells expressing the GFP-ABCG2 variants. The cells were labeled
by a monoclonal anti-ABCG2 antibody (5D3), and a phycoerythrin (PE) coupled anti-mouse IgG2b. The green fluorescence of
GFP-ABCG2 is plotted against 5D3-PE red fluorescence. Control HUES9 cells, HUES9 cells expressing GFP-ABCG2-R482R,
GFP-ABCG2-K86M, and GFP-ABCG2-R482G variants are shown. (C) Flow cytometry analysis of the pluripotency marker SSEA4 in
parental HUES9 cells and the GFP-ABCG2-expressing variants. The cells were labeled by a monoclonal anti-ABCG2 antibody (5D3)
visualized by a phycoerythrin (PE)-conjugated anti-mouse IgG2b, and by anti-SSEA4, conjugated to APC (green). HUES9 cells
expressing GFP-ABCG2-R482R, GFP-ABCG2-K86M, and GFP-ABCG2-R482G variants are shown.
https://doi.org/10.1371/journal.pone.0194925.g001
ABCG2 expression in hES cells
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expression of ABCB1 and ABCC1 in the pluripotent stem cells (S3 Fig). All these results sug-
gest that the overexpression of GFP-ABCG2 in these experiments does not change the pluripo-
tent state and growth properties of the hESCs.
Spontaneous and directed differentiation of the GFP-ABCG2 expressing
HUES9 clones
For investigating the spontaneous differentiation capacity of the GFP-ABCG2-hES cells into
cell types of the three germ layers, we differentiated the GFP-ABCG2-HUES9 cells via the
embryoid-body (EB) system (see Methods and [18]). As shown in Fig 2, after 6 days of EB for-
mation and a further 3 days differentiation on an adherent surface, we detected the expression
of the key markers specific for the three germ layers, that is β-III-Tubulin as an ectoderm
marker, alpha-fetoprotein (AFP) as an endoderm marker, and smooth muscle actin (SMA) as
a mesodermal marker protein. We found that these marker proteins were expressed in the dif-
ferentiated GFP-ABCG2-hESCs similarly to those in the parental hESCs (see Fig 2).
In order to follow the effects of the GFP-ABCG2 transgene expression on spontaneous
hESC differentiation, we have also measured a set of mRNA expression levels, characteristic
either for the pluripotent state (Oct-4 and NANOG), for ectodermal differentiation (Pax6),
endoderm formation (AFP), or mesoderm formation (Brachyury), by real-time PCR (S2 Fig).
Again, we found no difference in the expression patterns of these markers between the trans-
genic and the parental clones. These results collectively indicate that there are no significant
differences between spontaneous differentiation capacity of the GFP-ABCG2-hES and that of
the parental hESCs.
When examining the differentiation capacity of the GFP-ABCG2-hESC clones in the direction
of hepatocytes, we used protocols for hepatocyte differentiation according to references [20] and
[21], adapted to HUES9 cells (see Methods). When measuring the mRNA expression of the
ABCB11 transporter, and several other hepatocyte specific genes (HNF4, AFP, ALB) in the undif-
ferentiated cells and in the differentiated hepatocytes by real-time PCR, we found no significant
differences in the expression patterns of these markers in the GFP-ABCG2 expressing versus the
parental hESCs (S4 Fig). Moreover, when performing antibody–based immunocytochemistry
studies in the differentiated hepatocytes, we found a co-expression of AFP, HNF4, CK18 and
GFP-ABCG2 (Fig 3A and S5 Fig). These results suggest that the overexpression of GFP-ABCG2
does not affect the directed differentiation capacity of the hESCs into hepatocytes.
Since protein expression driven by the CAG promoter is expected to result in especially
high levels in cardiac tissues [13,23], we focused on studying the ABCG2 expression in cardio-
myocytes. In order to examine the effects of transgene expression on cardiomyocyte differenti-
ation, we isolated beating cardiomyocyte colonies derived from parental or GFP-ABCG2
expressing hESCs mechanically. In all cell clones expressing the GFP-ABCG2 variants we
could obtain beating cardiomyocyte colonies in similar numbers. As shown in confocal
microscopy measurements, presented in Fig 3B, the cardiomyocytes derived from the
GFP-ABCG2-R482G hESCs co-express the cTnI and the GFP-ABCG2 protein. All these data
indicate that stable expression of GFP-ABCG2 does not significantly affect cardiomyocyte dif-
ferentiation from HUES9 cells, and in these cells pacemaker and contractile activities are pre-
served. The videos presented in the S Information confirm the similar beating activity of the
cardiomyocytes derived from the parental or GFP-ABCG2 expressing hESCs.
GFP-ABCG2 functional studies in hES cells
After the investigation of the basic characteristic of the GFP-ABCG2-hESCs we analyzed the
function of the GFP-ABCG2 in these pluripotent cells. In the following measurements we
ABCG2 expression in hES cells
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focused on functional variants i.e. GFP-ABCG2wt and GFP-ABCG2 R482G. As documented
above, confocal microscopy measurements showed that a large fraction of the GFP-ABCG2 is
localized in the plasma membrane, and in the following experiments we assessed the transport
function of the plasma membrane GFP-ABCG2 by measuring the extrusion of a known sub-
strate of ABCG2, DyeCycleViolet (DCV), a fluorescent nuclear stain [24–26].
In the experiments shown in Fig 4A, hESCs were incubated with 100 nM DCV for 16
hours, in the presence or absence of the ABCG2-specific inhibitor, Ko143. The DCV fluores-
cent signal, representing DNA-bound DCV, was followed in the cells by flow-cytometry analy-
sis. According to these results, hESCs expressing the wt GFP-ABCG2 or the GFP-ABCG2-
R482G have significantly higher DCV extrusion capacity than the parental hESCs (transport
activity factors were Fparental = 56.65±10.54; FR482R = 82.22±1.86 p = 0.014; FR482G = 78.60
±2.26 p = 0.024).
In Fig 4B we document that functional ABCG2 overexpression and higher dye extrusion
capacity in the HUES9 cells results in a protective effect against mitoxantrone (MX). In these
experiments we incubated the GFP-ABCG2-hESCs and the parental hES cells in media con-
taining 5–200 nM MX respectively, and the survival of the cells was measured by flow-cytome-
try. These results show that while parental hES cells die at low concentration of MX, the hESCs
Fig 2. Spontaneous differentiation capacity of the parental HUES9 cells and HUES9 cells expressing GFP-ABCG2 variants—confocal microscopy analysis.
Both the parental and the GFP-ABCG2 expressing HUES9 cells express the marker proteins β-III-Tubulin, SMA and AFP (red). Nuclei are stained by DAPI (blue).
https://doi.org/10.1371/journal.pone.0194925.g002
ABCG2 expression in hES cells
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expressing the wild-type or the GFP-ABCG2-R482G proteins, tolerate MX in much higher
concentrations.
Cardiomyocytes derived from the hESCs expressing the
GFP-ABCG2-R482G protein show doxorubicin resistance
As shown above, we successfully isolated beating cardiomyocytes (see also S videos), express-
ing the cardiomyocyte specific Troponin-I (cTnI), derived from hESCs clones expressing
GFP-ABCG2-R482G. In these cardiomyocytes we examined a potential protective effect of the
overexpressed GFP-ABCG2-R482G against the cardiotoxic anticancer agent, doxorubicin
(DOX). The R482G ABCG2 variant was selected for these experiments because its higher
reported transport activity regarding DOX (see [14]).
As shown in Fig 5, hESC-derived cardiomyocytes overexpressing the GFP-ABCG2-R482G
protein were significantly protected against doxorubicin (DOX) accumulation. The cellular
fluorescence of DOX was significantly lower in hESCs-derived cardiomyocytes expressing the
Fig 3. Directed differentiation of HUES9 cells expressing GFP-ABCG2 into hepatocytes (A) and cardiomyocytes (B).
Confocal immunostainings (A) Co-immunostaining of AFP and GFP-ABCG2 in hepatocytes differentiated from HUES9
cells. Anti-GFP: green, AFP: red, nuclei: blue (B) Co-immunostaining of cardiac troponin I (red) and GFP-ABCG2 (green) in
cardiomyocytes differentiated from HUES9 cells. Cell nuclei are stained with DAPI (blue).
https://doi.org/10.1371/journal.pone.0194925.g003
ABCG2 expression in hES cells
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GFP-ABCG2-R482G protein, than that in the parental hESC-derived cardiomyocytes. More-
over, the cell killing effect of DOX was also much less pronounced in the GFP-ABCG2-R482G
expressing cells. In a compilation of three different DOX-treatment experiments, we found
that at relatively low doses (3 μM), after 16 hours of DOX treatment, the parental HUES-
derived cardiomyocytes had a live/dead cell ratio of 1.59 (live cells: 61,32% ± 41,11%; dead
cells: 38,68% ± 36,77%), while this ratio in the HUES9-GFP-ABCG2-R482G-derived cardio-
myocytes was 4.05 (live cells: 80,19% ± 13,85%; dead cells: 19,80% ± 11,30%).
Fig 4. Functional analysis of ABCG2 in EGFP-HUES9 (control) and GFP-ABCG2 expressing cells (A) Examination of
the transport function of the GFP-ABCG2 protein variants in HUES9 cells by measuring DCV uptake. Cellular DCV
fluorescence was measured in cells expressing the R482R (wild-type) and R482G (substrate mutant) variants of
GFP-ABCG2. The purple histogram shows the signal of the DCV in the control cells and the green histogram shows the
signal of DCV in the Ko143-treated cells. (B) Analysis of mitoxantrone cytotoxicity in EGFP-HUES9 (control) cells and in
HUES9 cells expressing GFP-ABCG2 variants. Survival of parental and GFP-ABCG2 expressing HUES9 cells was measured
in the presence of 5–200 nM Mitoxantrone (MX) by flow- cytometry. The ratio of the dead and living cells was calculated
on the basis of propidium-iodide accumulation and was normalized to untreated cells. Values represent the means±S.D. of
3 independent experiments. Significant differences (Student’s t-test, P<0.01) in the survival of parental and ABCG2-
variants expressing clones are indicated by asterisks. The exact mean±S.D. and p values are presented in S1 Table.
https://doi.org/10.1371/journal.pone.0194925.g004
ABCG2 expression in hES cells
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Discussion
The ABCG2 membrane protein, with divergent physiological and pathological functions, has
attracted much attention in recent cell biology studies. This ABC transporter was first recog-
nized as a multidrug efflux pump, protecting cancer cells against a wide range of chemothera-
peutic agents [27], but consequent investigations documented its important role in the
protection of the human body against a wide range of xeno- and endobiotics. ABCG2 is a key
efflux transporter in the intestine, in the blood-brain barrier and in the placenta, and has a
major role as a transporter in the liver and the kidney as well [28–30]. Regarding endobiotics,
ABCG2 was shown to transport harmful porphyrin metabolites out of the human cells, and
being involved in the excretion of bile acids and other toxic steroid metabolites [4,5], as well as
the elimination of the end-product of human purine metabolism, uric acid. This latter role was
emphasized by the GWAS studies showing the role of polymorphic variants of ABCG2 in gout
formation [31,32]. Interestingly, based on mouse knock-out studies, and the presence of
human individuals with no functional ABCG2 protein expression (with Jn negative blood
group–see refs [33,34]), the lack of this protein does not cause a direct life-threatening effect,
and only becomes important in responding to unfavorable environmental conditions, e.g.
toxin exposures.
There are numerous studies regarding the role of ABCG2 in tissue-derived and pluripotent
human stem cells. Hematopoietic and other regenerative tissues contain a so called side popu-
lation (SP), and these were shown to be multipotent stem cells, with high repopulation capacity
[35–38]. The stem cell like SP cells, found both in normal and cancerous tissues, are character-
ized by an increased Hoechst dye extrusion, due to a high expression of the ABCG2 trans-
porter. It has been widely accepted that human pluripotent stem cells also express the ABCG2
Fig 5. Beating cardiomyocyte colonies derived from HUES9 cells, incubated with doxorubicin (DOX, 3 μM) for 16 hours. DOX accumulation in the
cells was assessed by confocal microscopy (see Methods). (A) Cardiomyocytes differentiated from parental HUES9 cells, (B) cardiomyocytes differentiated
from HUES9 cells expressing GFP-ABCG2-R482G.
https://doi.org/10.1371/journal.pone.0194925.g005
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transporter. Most studies (10 out of 11) showed ABCG2 expression at the mRNA level (except
for Zheng H et al. [39]). It should however be noted that the protein expression levels always
exhibited heterogeneous distribution, and its extent varied in examined cell lines, depending
also on the culture conditions ([10,40,41]as reviewed in [9]).
Still, there are no relevant studies as yet regarding the effects of stable ABCG2 overexpres-
sion in human pluripotent stem cells and in their differentiated derivatives. Therefore in the
present experiments we have decided to investigate these potential effects by a stable expres-
sion of the GFP tagged human ABCG2 protein in the human embryonic stem cell line,
HUES9. We have shown earlier that the GFP-tagged ABCG2 is fully functional [12], and thus
can be used both for functional and cellular localization studies. The low transfection efficiency
usually characteristic for the human pluripotent stem cells, the difficulty of live cell selection
and single-cell cloning, as well as the long-term cell differentiation protocols requiring special
factors and conditions, were major hurdles in these experiments. Therefore we used molecular
biology constructs, gene delivery and integration methods, and fluorescent GFP-tagged
ABCG2 membrane proteins, which proved already usable in our earlier studies, and thus pro-
vided a supporting background for the current studies. The Sleeping Beauty transposon system
used here was shown to provide preferentially random transgene integration [42], and we
selected transgenic cells with low integrated copy numbers, to avoid major genetic alterations.
The use of multiple transgenic hES cell clones in this study ensured that some untoward gene
alteration could not alter the overall results.
As documented in detail, we found that the stable overexpression of the GFP-tagged wild-
type and a mutant variant of the ABCG2 did not change the basic characteristics of hESCs. We
found no differences between the parental and the GFP-ABCG2 expressing hESCs in their
spontaneous and targeted differentiation capacity. However, the functional presence of the
overexpressed ABCG2 protein was clearly reflected in an increased DCV dye extrusion capac-
ity and a protection against toxic drugs, e.g. mitoxantrone and doxorubicin.
As shown here, the overexpression of a functional GFP-ABCG2 protected the hESCs
against mitoxantrone toxicity (see Fig 4B). This was true both for the wild-type ABCG2 and
the substrate mutant functional variant of ABCG2-R482G. Thus, by a stable expression of a
relatively small amount of functional ABCG2 membrane protein, this technology allows the
generation of selected toxin-resistant pluripotent human stem cells.
An important finding in our current study is the strong protective effect of ABCG2 expres-
sion in the hESC-derived cardiomyocytes against doxorubicin (DOX) toxicity (see Fig 5).
Doxorubicin has a widely observed cardiotoxicity which limits its use as a potent anticancer
agent. In the case of human pluripotent stem cell-derived cardiomyocytes it has been shown
that DOX exposure causes dose-dependent increases in apoptotic and necrotic cell death, reac-
tive oxygen species production, mitochondrial dysfunction and increased intracellular calcium
concentrations [43]. Here we demonstrate that DOX toxicity is strongly reduced in cardio-
myocytes expressing the ABCG2 protein, especially when the ABCG2-R482G variant is used,
which has better DOX transporting properties than the wild-type ABCG2. Still, cardiac differ-
entiation or contractile and signal generation functions were found to be unaltered in these
cells. Since in normal human cardiomyocytes the expression of the ABCG2 transporter is prac-
tically absent [44,45], our current findings may help to devise gene-modified cardiac cells pro-
tected against toxic agents.
As a summary, we have shown here that a stable overexpression of GFP-tagged ABCG2
multidrug transporter does not change the pluripotency or the spontaneous and targeted dif-
ferentiation features of human pluripotent stem cells. The use of these transgenic cells may
help us to better understand the function and localization of ABCG2 during tissue
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differentiation from human stem cells, as well as to engineer toxin-resistant human stem cell
derived tissues.
Conclusions
We have generated human embryonic stem cells stably overexpressing the wild-type and a
substrate-mutant GFP-ABCG2 fusion protein. ABCG2 overexpression did not change the
pluripotency, growth, and the spontaneous or targeted differentiation properties of the hESCs.
Still, the overexpression of a functional GFP-ABCG2 provided increased resistance in hESCs
against mitoxantrone, and protected the hESC-derived cardiomyocytes against doxorubicin
toxicity. These studies indicate that while ABCG2 expression does not significantly influence
basic stem cell properties, the expression of this multidrug transporter provides toxin-resis-
tance to pluripotent stem cells or stem cell derived tissues.
Supporting information
S1 Fig. The Sleeping Beauty (SB) transposon vector used for the stable expression of the
GFP-ABCG2 fusion protein. The transposon cassette also contains a puromycin resistance
gene expression unit which allowed us to select the integrated transposon containing cells by
applying this antibiotic. IRDR-(L)/(R)–left and right inverted repeat direct repeat SB transpo-
son sequences; Puro–puromycin resistance gene; Amp res–ampicillin resistance gene; F1 ori /
ColE-or: bacterial replication origins; polyA: polyadenylation sequences.
(TIF)
S2 Fig. mRNA expression during spontaneous differentiation of parental HUES9 cells and
HUES9 cells stably expressing the GFP-ABCG2 variants. Spontaneous differentiation was
performed via embryoid body (EB) formation system. After 6 days EBs were placed onto gela-
tin coated 24 well plates, where they underwent spontaneous differentiation. We collected
samples for mRNA expression analysis before differentiation (at day 0) and at 6, 12, and 18
days of differentiation (for details see Methods). S2 Fig shows the mRNA levels of the Oct-4
and Nanog (pluripotent), AFP (endoderm), T (Brachyury) (mesoderm) and Pax6 (ectoderm)
markers. The PRLP0 ribosomal protein mRNA expression was used as the internal control for
quantification. Figures shows the relative mRNA levels to PRLP0 and were normalized to the
undifferentiated HUES9 (d0) samples. Values represent the means±S.D. of 3 independent
experiments.
(TIF)
S3 Fig. mRNA expression in undifferentiated state of parental HUES9 cells and HUES9
cells stably expressing the GFP-ABCG2 variants. We collected samples for mRNA expres-
sion analysis before differentiation and measured the expression levels of the ABCG2, ABCB1
and ABCC1 transporters. The PRLP0 ribosomal protein mRNA expression was used as the
internal control for quantification. Values represent the means±S.D. of 2 independent experi-
ments.
(TIF)
S4 Fig. mRNA expression in undifferentiated state and after a directed hepatocyte differ-
entiation of parental HUES9 cells and HUES9 cells stably expressing the GFP-ABCG2 vari-
ants. We collected samples for mRNA expression analysis before differentiation (“stem”
samples) and at 18 days of differentiation (“hepatic” samples) (for details see Methods). We
measured the expression levels of the Oct-4, AFP, ALB, ABCB11 and HNF4 markers. The
PRLP0 ribosomal protein mRNA expression was used as the internal control for
ABCG2 expression in hES cells
PLOS ONE | https://doi.org/10.1371/journal.pone.0194925 April 12, 2018 13 / 17
quantification. Values represent the means±S.D. of 2 independent experiments.
(TIF)
S5 Fig. Directed differentiation of HUES9 cells expressing GFP-ABCG2 into hepatocytes.
Immunostaining analysis of CK18 and HNF4 hepatocyte markers by confocal microscopy.
Co-immunostaining of CK18 or HNF4 and GFP-ABCG2 in hepatocytes differentiated from
HUES9 cells. Anti-GFP: green, CK18 or HNF4: red, nuclei: blue.
(TIF)
S1 Table. Mitoxantrone cytotoxicity in EGFP-HUES9 (control) cells and in HUES9 cells
expressing GFP-ABCG2 variants. The ratio of the dead and living cells was calculated on the
basis of propidium-iodide accumulation and was normalized to untreated cells. Values repre-
sent the means±S.D. of 3 independent experiments. Significant differences (Student’s t-test,
P<0.01) in the survival of parental and ABCG2-variants expressing clones are indicated by
asterisks.
(TIF)
S1 Video. HUES9-GFPG2-R482G beating cardiomyocytes.
(MP4)
S2 Video. HUES9 beating cardiomyocytes.
(MP4)
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